Cancer Genetics Inc. (NASDAQ:CGIX)’s share price traded up 9.4% on Friday . The company traded as high as $2.10 and last traded at $2.10, with a volume of 101,922 shares changing hands. The stock had previously closed at $1.92.

Separately, Zacks Investment Research lowered Cancer Genetics from a “buy” rating to a “hold” rating in a research report on Friday, July 29th.

The stock has a 50-day moving average of $2.04 and a 200-day moving average of $2.32. The company’s market cap is $29.62 million.

Cancer Genetics (NASDAQ:CGIX) last released its quarterly earnings results on Wednesday, August 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.05. The company had revenue of $7 million for the quarter, compared to the consensus estimate of $6.50 million. During the same period in the prior year, the firm posted ($0.51) EPS. The business’s revenue for the quarter was up 67.3% on a year-over-year basis. Equities research analysts predict that Cancer Genetics Inc. will post ($1.19) earnings per share for the current year.

Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.